News from onclive.comFollowNews from onclive.comYour destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.We’ve aggregated 573 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today. We’ve aggregated 573 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about onclive.comWhere is onclive.com located?onclive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top onclive.com NewsBreast Cancer · United StatesFDA expands use of Kisqali to early stage breast cancer patients75% Center coverage: 4 sourcesWomen with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.See the StoryEli Lilly · United StatesLilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)100% Right coverage: 1 sourcesEli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.See the StoryAstraZeneca · United StatesFDA Expands Approval of Osimertinib in Lung Cancer100% Center coverage: 1 sourcesThe FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, theSee the StoryLatest News StoriesTopics Most Covered by onclive.comCancerBreast CancerMerckFDASocial MediaCancerBreast CancerMerckSources Covering Similar Topicstargetedonc.comcancernetwork.comstocktitan.netPharmacy Timescuretoday.comtargetedonc.comcancernetwork.comstocktitan.netSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to onclive.comMarylandBreast CancerCalifornia, United StatesCancerUnited States